Type IIa hyperlipoproteinaemia. An evaluation of four therapeutic regimens.
The cholesterol-lowering effect of clofibrate (Ciba-SU13437) cholestyramine and the combination of clofibrate and cholestyramine is studied in 19 subjects with type lla hyperlipoproteinaemia, over a 20-week period. Each regimen is evaluated in terms of total cholesterol-lowering effect, cholesterol-lowering effect at 4, 8 and 16 weeks of therapy, and the incidence of side-effects. Cholestyramine is identified as the agent of choice in the management of this disorder and recommendations for its optimal utilisation are put forward.
D000293:Adolescent; D000328:Adult; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D002792:Cholestyramine Resin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000009:adverse effects / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D011422:Propionates; D002792:Cholestyramine Resin; D002784:Cholesterol; D002994:Clofibrate